Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term, priority isotope access for Telix’s alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs. First IBA alpha-beam […]





